Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Reckitt Benckiser new condom gets CE mark
Following the CE mark, CSD500 has got license to be marketed in 29 European countries and also in a number of non-European territories. Futura chief executive James Barder
Following the CE mark, CSD500 has got license to be marketed in 29 European countries and also in a number of non-European territories. Futura chief executive James Barder
Qnexa is an once-a-day, oral, controlled-release investigational drug candidate designed to decrease appetite, increase satiety and to address weight loss, type 2 diabetes and obstructive sleep apnea. The
The new organisation will run under the name Pharma KPO and will be incorporated in Singapore. Pharma KPO aims to take advantage of business opportunities by providing processes
Halozyme’s net income was $3.12m, or $0.03 per diluted share, compared to net loss of $12.15m, or $0.13 loss per diluted share, for the same period in 2010.
The increase in revenues primarily reflects gains in sales of the company’s products and services from its API, contract research and manufacturing and peptides synthesis businesses. Neuland Labs
In the study, ICR researchers have investigated DNA of women from 911 families with breast and ovarian cancer and compared differences in DNA with a control group of
P&G’s net earnings were $2.51bn for the fourth quarter ended 30 June 2011, compared to $2.19bn, for the same period in 2010. The company’s operating income was $3.29bn,
Inovio Pharma’s net loss was $2.84m or $0.02 loss per diluted share, compared to $7.61m, or $0.07 per diluted share, for the same period in 2010. The company’s
The Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity’s (NDO) decision is supported by the results of Phase III programme evaluating
The company’s loss from operations for the second quarter of 2011 was $6.28m, compared to $5.36m for the same period in 2010. For the six months ended 30